Solid IO is a medtech startup spun out of the University of Helsinki that has developed a tumour-on-chip platform replicating a patient's tumour microenvironment to generate real-time, biologically relevant data on treatment response. Its platform is designed to help clinicians select the most effective immunotherapies and combination treatments from day one, reducing unnecessary side effects and eliminating trial-and-error approaches. The technology also targets pharmaceutical R&D and clinical trials by enabling early patient stratification, biomarker validation, and treatment-response modelling. Solid IO has demonstrated proof of concept, published its first scientific paper in October 2024, and is finalising preclinical studies. The company plans to secure a clinical validation partner and begin clinical trials next year, and is targeting the US market first because its product will be classified as an in vitro diagnostic (IVD) device under a single regulatory framework. The recently closed €800,000 funding will be used to plan and execute clinical trials, build the regulatory strategy, and prepare for US market entry.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2025